ZLMT-12

Overview

ZLMT-12 (compound 35), tacrine derivatives, is a potent, orally active CDK2/9 inhibitor with IC 50 values of 0.002 and 0.011 μM for CDK9 and CDK2 , respectively. ZLMT-12 has a weak inhibitory effect on AChE ( IC 50 =19.023 μM) and BChE ( IC 50 =2.768 μM). ZLMT-12 has low toxicity and antiproliferative activity. ZLMT-12 induces apoptosis and arrests the cell cycle in the S phase and G2/M phase.

Application

Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Cholinesterase (ChE) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-151436
• CAS No.: 2841473-39-8
• Molecular Formula: C26H31ClN6O
• Molecular Weight: 479.02
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source